Abstract 115P
Background
Trifluridine/tipiracil (lonsurf) and regorafenib are standard of treatment in patients with chemo-refractory metastatic colorectal cancer (mCRC). Our study aimed to investigate the impact of sidedness on survival in patients with mCRC treated with lonsurf or regorafenib.
Methods
Patients who were diagnosed with mCRC and treated with lonsurf or regorafenib between 2015 and 2022 were retrospectively identified from Taiwan National Health Insurance Research Database and Taiwan Cancer Registry. Propensity score matching was used to reduce the selection bias. The oncologic outcomes were presented with time to treatment failure (TTF) and overall survival (OS).
Results
A total of 4665 patients were identified. After matching, 752 patients were analyzed for outcomes comparison, including 376 patients in each group. In general, median TTF and OS were 1.9 months versus 2.0 months (p = 0.701)and 9.1 months versus 7.0 months (p = 0.008) in lonsurf and regorafenib, respectively. Patients were stratified by sidedness, including 297 left side mCRC in each group and 79 right side mCRC in each group. For patients with left side colon, median TTF and OS were 1.9 months versus 2.0 months (p = 0.178) and 10.2 months versus 7.8 months (p = 0.006) in lonsurf and regorafenib, respectively, while for patients with right side colon, median TTF and OS were 1.8 months versus 1.8 months (p = 0.390) and 7.8 months versus 6.0 months (p = 0.011) in lonsurf and regorafenib, respectively.
Conclusions
Lonsurf provided a longer survival over regorafenib in mCRC patients regardless of sidedness of primary tumor location.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract